Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase II for Castration-Resistant Prostate Cancer (CRPC). According to GlobalData, Phase II drugs for Castration-Resistant Prostate Cancer (CRPC) have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lutetium Lu 177 vipivotide tetraxetan’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Lutetium Lu 177 Vipivotide Tetraxetan in Castration-Resistant Prostate Cancer (CRPC)

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lutetium Lu 177 vipivotide tetraxetan overview

lutetium Lu 177 vipivotide tetraxetan (Pluvicto) is a radioligand therapeutic agent. It is formulated as solution for intravenous route of administration. Pluvicto is indicated for the treatment of  adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
AAA-617 (177Lu-PSMA-617) is under development for the treatment of adenoid cystic carcinoma, metastatic hormone sensitive prostate cancer (mHSPC), non metastatic castration-resistant prostate cancer(CRPC), castration-resistant prostate cancer, metastatic hormone-naive prostate cancer (mHNPC). It is administered through intravenous route. The drug candidate is a peptide drug conjugate, consisting of PSMA-617 which is conjugated to radioligand 177-Lu. It acts by targeting PSMA.
It was under development for the treatment of hormone-sensitive prostate cancer.

Advanced Accelerator Applications overview

Advanced Accelerator Applications (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company develops new medicines which targets the orphan diseases in the field of cardiology, oncology, neurology and inflammation. The company is also involved in manufacturing Positron Emission tomography (PET) and single-photon emission computed tomography (SPECT). It’s key brand portfolio comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnascan, Fluorochol, AAACholine, Cholscan, Lysakare, Dopaview, Padoview and Lumark. AAA is headquartered in Rueil-Malmaison Cedex, Ile-de-France, France.

For a complete picture of Lutetium Lu 177 vipivotide tetraxetan’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.